CAS 306296-47-9: Vicriviroc

Vicriviroc is an investigational pharmaceutical compound, specifically classified as an HIV entry inhibitor. It originates from a synthetic source, designed to target the CCR5 co-receptor on human immune cells. The mode of action involves blocking this co-receptor, thereby preventing the HIV virus from binding and fusing with the host cell membrane. This inhibition effectively obstructs the virus's ability to enter and infect the host cells, particularly those within the chemokine receptor family. Vicriviroc's primary use is as a potential antiretroviral agent in the treatment of HIV-1 infection. Its application focuses on patients whose strains of HIV predominantly use the CCR5 receptor for cellular entry. By interfering with the virus's entry mechanism, Vicriviroc aims to reduce viral load and impede disease progression. Although it has shown promise in clinical trials, ongoing research and development continue to evaluate its efficacy and safety in comparison to existing therapeutic options.

Vicriviroc, also known as MK4176 is a CCR5 antagonist.